{"title":"Co-trimoxazole prophylaxis against opportunistic infections is safe, and effective in HIV-infected children","authors":"","doi":"10.1016/j.ehbc.2005.03.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Question</h3><p>Does co-trimoxazole prophylaxis against opportunistic infections reduce mortality and hospital admissions in HIV-infected children more than 1 year old?</p></div><div><h3>Study design</h3><p>Double blind randomised controlled trial.</p></div><div><h3>Main results</h3><p>In HIV-infected children more than 1 year old, co-trimoxazole prophylaxis against opportunistic infections reduced deaths and hospital admissions compared with placebo at nearly 19 months. The number of treatment related adverse events were similar in both groups (see results table).</p></div><div><h3>Authors’ conclusions</h3><p>Children with HIV infection should receive cotrimoxazole prophylaxis in resource-poor settings, despite local bacterial resistance to this drug.</p></div>","PeriodicalId":100513,"journal":{"name":"Evidence-based Healthcare and Public Health","volume":"9 3","pages":"Pages 235-236"},"PeriodicalIF":0.0000,"publicationDate":"2005-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ehbc.2005.03.005","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence-based Healthcare and Public Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1744224905000598","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Question
Does co-trimoxazole prophylaxis against opportunistic infections reduce mortality and hospital admissions in HIV-infected children more than 1 year old?
Study design
Double blind randomised controlled trial.
Main results
In HIV-infected children more than 1 year old, co-trimoxazole prophylaxis against opportunistic infections reduced deaths and hospital admissions compared with placebo at nearly 19 months. The number of treatment related adverse events were similar in both groups (see results table).
Authors’ conclusions
Children with HIV infection should receive cotrimoxazole prophylaxis in resource-poor settings, despite local bacterial resistance to this drug.